On 10 August 2026, Amneal Pharmaceuticals announced the completion of its acquisition of Kashiv BioSciences. This follows the companies entering into a definitive agreement in April 2026, and is in line with their expectations of a H2/2026 closing.
The acquisition combines Kashiv’s expertise in biosimilar development and manufacturing with Amneal’s scale and commercialisation capabilities. According to Amneal, it creates “an integrated biosimilars business that can launch multiple biosimilars each year” and extend Amneal’s “growth profile into the next decade”.
The acquisition included a USD $375 million cash transaction and USD $375 million in equity payable at closing, with up to USD $350 million based on achievement of certain regulatory milestones, potential royalties based on commercial milestones, and funding of operations through closing.
Kashiv and Amneal have previously entered strategic partnerships in relation to biosimilars in the US, including Fylnetra™ (biosimilar pegfilgrastim) in May 2022 and ADL018 (biosimilar omalizumab) in 2024.
The acquisition brings together Kashiv’s biosimilar pipeline (including Releuko™ (filgrastim-ayow) (FDA-approved March 2022), abatacept/KSHB002 (in clinical trials), certolizumab pegol and nivolumab (pre-clinical) and pembrolizumab (cell line and process development)) with Amneal’s biosimilar pipeline (including Alymsys® (bevacizumab) (FDA approved April 2022) and the exclusive US rights to mAbxience’s Boncresa™ and Oziltus™ (MB09), biosimilars to Amgen’s Prolia® and Xgeva® (denosumab) (FDA approved December 2025)).